Approval and delay status of United States -approved new drugs (2010-2023) in European Union, Japan, and China.

Mo Q, He J, Guo Q, Wei H, Liu Y, Yang Y

Open source

DOI
10.1186/s12913-026-15081-1
Published
2026 Jul 13
Container
BMC health services research
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12913-026-15081-1,
  title = {Approval and delay status of United States -approved new drugs (2010-2023) in European Union, Japan, and China.},
  author = {Mo Q and He J and Guo Q and Wei H and Liu Y and Yang Y},
  year = {2026},
  journal = {BMC health services research},
  doi = {10.1186/s12913-026-15081-1},
  url = {https://doi.org/10.1186/s12913-026-15081-1}
}

RIS

TY  - JOUR
TI  - Approval and delay status of United States -approved new drugs (2010-2023) in European Union, Japan, and China.
AU  - Mo Q
AU  - He J
AU  - Guo Q
AU  - Wei H
AU  - Liu Y
AU  - Yang Y
PY  - 2026
JO  - BMC health services research
DO  - 10.1186/s12913-026-15081-1
UR  - https://doi.org/10.1186/s12913-026-15081-1
ER  - 

APA

Q, M., J, H., Q, G., H, W., Y, L., & Y, Y. (2026). Approval and delay status of United States -approved new drugs (2010-2023) in European Union, Japan, and China.. BMC health services research. https://doi.org/10.1186/s12913-026-15081-1

Source records